Indiana life sciences companies capture more venture capital money in first half of 2010
Venture dollars for Hoosier companies are still few, but the flow of deals is picking up.
Life Science & Biotech
Articles
UPDATE: Patent expirations overshadow Lilly profits
Investors are focused on whether Eli Lilly and Co. can continue dividend payments when patent expirations hit in the new few
years and whether the company's drug development pipeline can replace lost revenue.
Lilly’s second-quarter profits surge 16 percent
Indianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months
ended June 30,
even after paying $27 million in severance to laid off employees.
New rules raise stakes for Lilly drug
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
Lilly’s Lechleiter: No change in plans
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
Marcadia enlists Lilly to help develop new diabetes drug
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
Q&A
David Stocum is the director of the Center for Regenerative Biology and Medicine at the IUPUI School of Science.
He and his team are studying how amphibians regenerate parts of their bodies to see if there are ways to induce humans to
regenerate tissue that is lost or damaged. The center has about 20 researchers and funding of about $14 million to fuel its
quest.
Promising ethanol yeast nears market launch
A firm that may have developed a breakthrough yeast for ethanol production has landed new investment and high-octane board
members. Two-year-old Xylogenics Inc. also says it plans to license its first bioengineered yeast later this year.
AIT Labs moving headquarters, adding 160 jobs
The Indianapolis-based forensics, clinical and pharmaceutical testing firm, led by CEO Michael Evans, plans to invest $74
million to acquire and equip
an existing 90,000-square-foot building in Woodland Corporate Park near West 79th Street and Interstate 465.
Indiana’s biggest private companies majored in the basics in 2009
Health care, plastics, other fundamental consumer needs kept some companies on upswings.
UPDATE: Commission approves City Market funding
The Metropolitan Development Commission voted Wednesday afternoon to release nearly $4 million to
improve
the historic building in downtown Indianapolis.
Indiana Seed Fund nearing end of $6 million stash
Having invested in 10 companies since 2005 and with its $6 million pot of money running low, the Indiana Seed Fund is nearing
a crossroads.
OrthoWorx initiative names executive director
Not-for-profit launched last year by BioCrossroads and Indiana’s orthopedic companies names Zimmer Inc. executive Brad Bishop
to lead the initiative.
Cancer researcher battling Semafore in court
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
Indiana biofuel firm strikes ethanol licensing deal
A Purdue University-based company has reached a deal giving Chinese and Danish firms access to a patented product that makes
it easier to turn wood chips, grasses and other agricultural wastes into ethanol.
Indianapolis startup attacks Alzheimer’s disease
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual
property, and begin learning how to make a drug into a once-a-day pill.
Biopharma fueling boom in refrigerated warehousing
In the past few years, a handful of cold storage facilities have sprouted locally by playing to Indianapolis' strengths
in warehousing and life sciences.
Bioanalytical Systems reports loss in second quarter
Bioanalytical Systems Inc. narrowed its losses in the second fiscal quarter despite a 2 percent drop in revenue, the West
Lafayette-based contract research firm said late last week.
Bioanalytical Systems names new chief executive
West Lafayette-based Bioanalytical Systems Inc. has promoted Anthony S. Chilton to CEO following the retirement of top executive
Richard M. Shepperd earlier this year.
Indiana’s growth in life sciences jobs beats national average
Bloomington led the nation as the No. 1 small city in medical devices and equipment.